These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17892458

  • 1. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma.
    Liu Y, Chen L, He X, Fan L, Yang G, Chen X, Lin X, DU L, Li Z, Ye H, Mao Y, Zhao X, Wei Y.
    Int J Gynecol Cancer; 2008; 18(4):652-9. PubMed ID: 17892458
    [Abstract] [Full Text] [Related]

  • 2. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model.
    Jiang QQ, Fan LY, Yang GL, Guo WH, Hou WL, Chen LJ, Wei YQ.
    BMC Cancer; 2008 Aug 16; 8():242. PubMed ID: 18706101
    [Abstract] [Full Text] [Related]

  • 3. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
    Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, Hu J, Chen X, Wang X, Yuan Y, Tang M, Wen J, Wei Y.
    Phytother Res; 2008 Aug 16; 22(8):1125-32. PubMed ID: 18570244
    [Abstract] [Full Text] [Related]

  • 4. The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer.
    Liu P, Gou M, Yi T, Qi X, Xie C, Zhou S, Deng H, Wei Y, Zhao X.
    Int J Oncol; 2012 Oct 16; 41(4):1504-12. PubMed ID: 22825572
    [Abstract] [Full Text] [Related]

  • 5. Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.
    Luo H, Zhong Q, Chen LJ, Qi XR, Fu AF, Yang HS, Yang F, Lin HG, Wei YQ, Zhao X.
    J Cancer Res Clin Oncol; 2008 Sep 16; 134(9):937-45. PubMed ID: 18350317
    [Abstract] [Full Text] [Related]

  • 6. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells.
    Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, Chen L, Wei Y.
    Eur J Obstet Gynecol Reprod Biol; 2008 Sep 16; 140(1):95-102. PubMed ID: 18440692
    [Abstract] [Full Text] [Related]

  • 7. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
    Yokoyama Y, Xin B, Shigeto T, Mizunuma H.
    J Cancer Res Clin Oncol; 2011 Aug 16; 137(8):1219-28. PubMed ID: 21681689
    [Abstract] [Full Text] [Related]

  • 8. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W, Liang B, Yin J, Li X, Cheng J.
    Cell Biochem Biophys; 2015 May 16; 72(1):203-13. PubMed ID: 25510462
    [Abstract] [Full Text] [Related]

  • 9. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.
    Hu J, Chen LJ, Liu L, Chen X, Chen PL, Yang G, Hou WL, Tang MH, Zhang F, Wang XH, Zhao X, Wei YQ.
    Exp Mol Med; 2008 Dec 31; 40(6):617-28. PubMed ID: 19116447
    [Abstract] [Full Text] [Related]

  • 10. Synergistic effect of honokiol and 5-fluorouracil on apoptosis of oral squamous cell carcinoma cells.
    Ji N, Jiang L, Deng P, Xu H, Chen F, Liu J, Li J, Liao G, Zeng X, Lin Y, Feng M, Li L, Chen Q.
    J Oral Pathol Med; 2017 Mar 31; 46(3):201-207. PubMed ID: 27465776
    [Abstract] [Full Text] [Related]

  • 11. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers.
    Long Q, Xiel Y, Huang Y, Wu Q, Zhang H, Xiong S, Liu Y, Chen L, Wei Y, Zhao X, Gong C.
    J Biomed Nanotechnol; 2013 Jun 31; 9(6):965-75. PubMed ID: 23858960
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.
    Qi X, Song X, Liu P, Yi T, Li S, Xie C, Zheng Y, Bai Y, Sun C, Wei Y, Zhao X.
    Oncol Rep; 2011 Sep 31; 26(3):703-10. PubMed ID: 21667029
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):43-51. PubMed ID: 18588872
    [Abstract] [Full Text] [Related]

  • 14. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J, Sun L.
    Int J Oncol; 2018 Sep 04; 53(3):1055-1068. PubMed ID: 30015875
    [Abstract] [Full Text] [Related]

  • 15. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Ishikura N, Yorozu K, Kurasawa M, Yanagisawa M, Sugimoto M, Yamamoto K.
    Oncol Rep; 2019 Sep 04; 42(3):1057-1065. PubMed ID: 31322247
    [Abstract] [Full Text] [Related]

  • 16. Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction.
    Huang JS, Yao CJ, Chuang SE, Yeh CT, Lee LM, Chen RM, Chao WJ, Whang-Peng J, Lai GM.
    BMC Cancer; 2016 Mar 24; 16():245. PubMed ID: 27012679
    [Abstract] [Full Text] [Related]

  • 17. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI, Kim JH, Lee KT, Choi JH.
    Gynecol Oncol; 2011 Dec 24; 123(3):588-96. PubMed ID: 21945308
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effects of heparin-polyethyleneimine nanogels delivering claudin-3-targeted short hairpin RNA combined with low-dose cisplatin on ovarian cancer.
    Liu L, Gou M, Yi T, Bai Y, Wei Y, Zhao X.
    Oncol Rep; 2014 Apr 24; 31(4):1623-8. PubMed ID: 24482188
    [Abstract] [Full Text] [Related]

  • 19. Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
    Hu H, Huang G, Wang H, Li X, Wang X, Feng Y, Tan B, Chen T.
    Oncol Rep; 2018 Mar 24; 39(3):1191-1196. PubMed ID: 29286149
    [Abstract] [Full Text] [Related]

  • 20. Sequential combination therapy of ovarian cancer with cisplatin and γ-secretase inhibitor MK-0752.
    Chen X, Gong L, Ou R, Zheng Z, Chen J, Xie F, Huang X, Qiu J, Zhang W, Jiang Q, Yang Y, Zhu H, Shi Z, Yan X.
    Gynecol Oncol; 2016 Mar 24; 140(3):537-44. PubMed ID: 26704638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.